181 related articles for article (PubMed ID: 25377907)
1. Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.
Hagino H; Yoshida S; Hashimoto J; Matsunaga M; Tobinai M; Nakamura T
Calcif Tissue Int; 2014 Dec; 95(6):557-63. PubMed ID: 25377907
[TBL] [Abstract][Full Text] [Related]
2. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
3. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
Miller PD; Delmas PD; Huss H; Patel KM; Schimmer RC; Adami S; Recker RR
Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
[TBL] [Abstract][Full Text] [Related]
4. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Watts NB; Geusens P; Barton IP; Felsenberg D
J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
[TBL] [Abstract][Full Text] [Related]
5. Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
Ito M; Tobinai M; Yoshida S; Hashimoto J; Nakamura T
J Bone Miner Metab; 2017 Jan; 35(1):58-64. PubMed ID: 26614597
[TBL] [Abstract][Full Text] [Related]
6. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
8. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
[TBL] [Abstract][Full Text] [Related]
9. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
[TBL] [Abstract][Full Text] [Related]
10. Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
Nakano T; Yamamoto M; Hashimoto J; Tobinai M; Yoshida S; Nakamura T
J Bone Miner Metab; 2016 Nov; 34(6):678-684. PubMed ID: 26462480
[TBL] [Abstract][Full Text] [Related]
11. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
12. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Sebba AI
Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Nakamura T; Nakano T; Ito M; Hagino H; Hashimoto J; Tobinai M; Mizunuma H;
Calcif Tissue Int; 2013 Aug; 93(2):137-46. PubMed ID: 23644930
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
16. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis: non-hormonal treatment.
Rizzoli R
Climacteric; 2007 Oct; 10 Suppl 2():74-8. PubMed ID: 17882678
[TBL] [Abstract][Full Text] [Related]
18. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.
Sambrook P; Cranney A; Adachi JD
Curr Med Res Opin; 2010 Mar; 26(3):599-604. PubMed ID: 20055751
[TBL] [Abstract][Full Text] [Related]
19. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Gold DT; Safi W; Trinh H
Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
[TBL] [Abstract][Full Text] [Related]
20. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
Watts NB; Lindsay R; Li Z; Kasibhatla C; Brown J
Osteoporos Int; 2003 Jun; 14(5):437-41. PubMed ID: 12730756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]